The Diurnal Board combines many years of business acumen, first-hand intellectual property experience and financial expertise to support the company.

Non-Executive Chairman - Peter Allen

Peter Allen, BA ACA - Non-Executive Chairman

Peter Allen is non-executive Chairman of the Board of Directors of Diurnal and joined the Group in July 2015. Peter has over 20 years’ experience in senior board positions in a wide portfolio of healthcare companies. He is currently non-executive Chairman of AIM-quoted Advanced Medical Solutions plc, main market-quoted Future plc, AIM-quoted Clinigen plc, as well as privately owned Oxford Nanopore Technologies Ltd. Previously, Peter was Chairman and interim Chief Executive Officer of ProStrakan Group Plc and spent three years as Chairman of Proximagen Neuroscience Plc (now Proximagen Group Limited). Prior to this, he was Chief Financial Officer of Celltech Group plc between 1992 and 2004. In addition to managing Celltech’s flotation process in 1993, Peter played a key role in several strategic acquisitions, including Chiroscience Group plc, Medeva plc and Oxford Glycosciences plc. In 2003, Peter was also appointed Deputy Chief Executive Officer of Celltech until the Company was sold to UCB in 2004. Peter is a qualified chartered accountant by background and has a joint degree in Accountancy and Law.

Chief Executive Officer - Martin Whitaker

Martin Whitaker, BSc PhD - Chief Executive Officer

Martin Whitaker is Chief Executive Officer of Diurnal with overall responsibility for delivering the Group's commercial objectives. Martin has over 15 years' experience in the pharmaceutical industry and has led the Diurnal team to progress the Company’s lead products, Chronocort® and Infacort®, into pivotal Phase III clinical trials. Martin is also Director of D3 Pharma Limited which has successfully commercialised Plenachol®, a high dose Vitamin D product prescribed in the UK. Previously, Martin worked for Fusion IP plc with responsibility for commercialising research from the Medical School at the University of Sheffield.  Prior to this, Martin was Operations Director of Critical Pharmaceuticals Limited, a venture capital-backed drug delivery company spun out of the University of Nottingham developing long-acting growth hormone products. Martin is a biochemist by background and has a PhD in Pharmaceutical Science from the University of Nottingham and a BSc (Hons) in Biochemistry from Bristol University. Martin also spent a year working for the pharmaceutical company, Pfizer, in Sandwich (UK). He is Honorary Professor of Medical Innovation at The University of Sheffield.

Chief Financial Officer - Richard Bungay

Richard Bungay, BSc ACA - Chief Financial Officer

Richard Bungay is Chief Financial Officer of Diurnal. Richard has over 20 years’ experience in senior finance and strategic roles within the pharmaceutical and biotechnology sector, mostly recently as CFO and COO of Mereo BioPharma, a company focused on developing treatments for rare and specialty diseases. His prior experience includes CFO of Glide Technologies. CFO of Verona Pharma, CEO (formerly CFO) of Chroma Therapeutics, Director of Corporate Communications and Strategic Planning at Celltech and finance director of the Respiratory and Inflammation therapy area at AstraZeneca. He qualified as a chartered accountant with Deloitte and has a first class degree in Chemistry from Nottingham University. Mr Bungay is a non-executive director of Glide Technologies. 

Chief Scientific Officer - Richard Ross

Richard Ross, MBBS MD FRCP - Chief Scientific Officer

Richard Ross is a founding Director of Diurnal and Chief Scientific Officer and is contracted to perform work for the Group by the University pursuant to the terms of a secondment agreement and a research agreement. He is a Professor of Clinical Endocrinology and Head of the Academic Unit of Diabetes, Endocrinology and Metabolism at the University of Sheffield and was previously a Senior Lecturer at St. Bartholomew’s Hospital, London. Richard’s primary research interest is pituitary and adrenal disease with a particular focus on hormone replacement. His research has yielded over 200 papers, more than 30 granted patents and publications in Nature Medicine, Nature Reviews Endocrinology, Nature Genetics, The Lancet, The BMJ and PNAS. He has been a member of the editorial boards of Clinical Endocrinology and the Journal of Clinical Endocrinology and Metabolism and served as an elected member of the executive committees for the European Society of Endocrinology (Treasurer), the Society for Endocrinology and Growth Hormone Research Society.

Non-Executive Director, Board representative of IP Group plc - Sam Williams

Sam Williams, MA PhD - Non-Executive Director, Board representative of IP Group plc

Sam Williams has 18 years' experience in the biotechnology industry, both as a top-ranked equity analyst in the City and, subsequently, as an entrepreneur and Chief Executive. From 2002 to 2007 he worked at Lehman Brothers where he was ranked the number one European biotechnology equity analyst by Institutional Investor magazine three years in a row. Sam left Lehman Brothers in 2007 to establish Modern Biosciences (MBS), an IP Group Plc portfolio company focused on the development of novel treatments for chronic, inflammatory diseases. MBS’ lead drug for rheumatoid arthritis is currently in Phase 1 studies and is the subject of a £176m option and licensing agreement with Janssen Biotech Inc. (J&J), signed in November 2014. As well as being CEO of MBS, Sam oversees the biotechnology portfolio of the FTSE 250 company, IP Group plc, and sits on its Executive Committee. He is a board member of the UK BioIndustry Association (BIA), a non-executive director of Diurnal Group plc and C4X Discovery Holdings Plc, and serves on the Translational Awards Advisory Committee of the British Heart Foundation (BHF). Sam has a PhD from Cambridge University and an MA in Pure and Applied Biology from Oxford University.  Sam was appointed to the Board of Diurnal by IPG in October 2014.

Non-Executive Director, Board representative of Finance Wales - Alan Raymond

Alan Raymond, BSc PhD - Non-Executive Director, Board representative of Finance Wales

Alan Raymond is an industry veteran with over 30 years of international marketing and general management experience within the pharmaceutical and biomedical industry. Alan was appointed to the board of Diurnal Limited by Finance Wales in April 2015. Most recently, Alan was the Sales and Marketing Director at Aesica Pharmaceuticals Ltd. Aesica was subsequently acquired by Consort Medical plc in September 2014. During his career, Alan progressed through senior executive and marketing roles in Banner Pharmacaps, RP Scherer, Reckitt and Colman, Eli Lilly, and MSD, within the UK, Netherlands and Australia. Prior to his industrial career, Alan was a postdoctoral researcher in the Cardiothoracic Research Institute (London) and he holds a PhD in Invertebrate Neurobiology from St. Andrews University.

Independent Non-Executive Director - John Goddard

John Goddard, BA FCA MCT - Independent Non-Executive Director

John Goddard has had a distinguished career in the global pharmaceutical industry, the majority of which was with AstraZeneca, where he was ultimately Head of Group Strategic Planning and Business Development. Prior to his retirement from AstraZeneca in 2010, he was responsible for a 100 strong global team focused on M&A and licensing, which completed around 75 transactions in four years including several acquisitions, in-licensing and out-licensing of compounds and disposals. Latterly, Mr. Goddard became Chairman of two AstraZeneca subsidiaries, Aptium Oncology in the US and Astratech in Sweden. He is currently a non-executive director of Oxford Pharmascience plc and Intas Pharmaceuticals Limited. John is a Fellow of the Institute of Chartered Accountants and a Member of the Association of Corporate Treasurers. John joined the Group in November 2015.